Research & DevelopmentOphthalmology July 15, 2024 Merck enhances ophthalmology portfolio with EyeBio acquisition By PBR Staff Writer The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under
Cell Therapy April 23, 2024 BMS to boost CAR T cell therapy production with Cellares deal By PBR Staff Writer The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS
Approvals December 22, 2023 SELLAS receives orphan drug designation for PTCL therapy By PBR Staff Writer Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95
Respiratory June 30, 2023 GSK acquires pharma firm Bellus Health for $2bn By PBR Staff Writer Bellus focuses on improving the lives of individuals suffering from persistent cough. In April this year, GSK reached an agreement for the acquisition of Bellus Health. The takeover comprises the
Oncology April 5, 2023 Mosaic Therapeutics raises $28m from Series A round to advance oncology therapies By PBR Staff Writer It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds
Drug DiscoveryResearch & Development March 31, 2023 Talem, Xyphos sign agreement for potential cancer therapeutic candidates By PBR Staff Writer As part of the deal, both the entities will be involved in research activities to detect and improve LENSai in silico-generated antibodies. These antibodies are being developed as
Other Diseases March 2, 2023 Nexus Pharmaceuticals gets FDA approval for Emerphed pre-filled syringe By PBR Staff Writer The company claimed that its 10mL presentation is the only FDA-approved ready-to-administer 10mL pre-filled syringe available. Nexus Pharmaceuticals CEO and president Usman Ahmed said: “We are pleased to
Skin RashDrug Manufacturing February 27, 2023 Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI By PBR Staff Writer Earlier, TMB-001 received orphan drug designation from the EC to treat autosomal recessive congenital ichthyosis (ARCI). Timber Pharmaceuticals chairman and CEO John Koconis said: “We are pleased to
Oncology February 24, 2023 Xspray Pharma and Eversana sign agreement for US launch of cancer therapy By vbandhakavi Xspray Pharma will maintain financial and strategic control and grant exclusive commercialisation access to Eversana for supporting its Dasynoc launch. Dasynoc, pending approval from the Food and Drug
RegulationApprovals February 23, 2023 EMA grants ODD to Sage Therapeutics’ SAGE-718 to treat Huntington’s disease By PBR Staff Writer SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive